News

AstraZeneca‘s Breztri Aerosphere has been approved by the U.S. Food and Drug Administration (FDA) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Formerly known as PT010, Breztri Aerosphere is an inhaled therapy with three active components: the long-acting muscarinic antagonist…

Patients with chronic obstructive pulmonary disease (COPD) should be more cautious when taking metformin, a common medication used to treat diabetes. In patients with both COPD and type 2 diabetes mellitus (T2DM), metformin carries a higher risk for pneumonia, hospitalization for COPD, and invasive mechanical ventilation. This…

Younger patients report feeling a heavier burden and greater daily impact from the symptoms of chronic obstructive pulmonary disease (COPD) than older patients, a global survey has revealed. Physicians should thus optimize treatment for these younger patients, say researchers leading the survey. The findings were published in an article,…

The ProAir Digihaler, a digital inhaler designed for people with asthma and chronic obstructive pulmonary disease (COPD) to monitor their inhaler usage through the use of a mobile app, is now available by prescription in the U.S. The albuterol inhaler (albuterol sulfate, 117 micrograms), developed by Teva…

Chronic obstructive pulmonary disease (COPD) appears to be a risk factor for lung cancer, liver cancer, and colorectal cancer, regardless of smoking status, a data study from Korea reported. The study, “Cancer development in patients with COPD: a retrospective analysis of the National Health Insurance Service-National…

Breztri Aerosphere, AstraZeneca’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with moderate to very severe forms of the disease, a Phase 3 trial shows. The findings were presented…

A vitamin D deficiency in people with chronic obstructive pulmonary disease (COPD) is associated with a decline in lung function, and with increased odds of acute exacerbations, a large-scale analysis found.  These results identify vitamin D as a potential biomarker…

Starting a pulmonary rehabilitation program within three months of hospitalization for chronic obstructive pulmonary disease, or COPD, improved the rate of survival over one year by 6.7%, according to new research. The study, “Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year…

Having small airways compared to lung size may contribute to the development of chronic obstructive pulmonary disease (COPD) in many non-smokers, a retrospective study has found. The finding broadens understanding of the risk factors involved in COPD, say  Columbia University Irving Medical Center researchers, whose work, “Association of Dysanapsis…

Nuvaira‘s Lung Denervation System, under clinical investigation for its use in treating chronic obstructive pulmonary disease (COPD), has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). This designation is given to devices that have the potential to substantially improve the…